Six Form 483 observations of GMP deficiencies have been received from the US FDA by Biocon after the agency inspected the Malaysian manufacturing facility for its insulin aspart biosimilar. However, the Indian firm – which is partnered with Viatris on the product, for which an interchangeability designation is also being sought – insisted that US commercialization plans would not be affected.
Biocon has received from the US Food and Drug Administration six Form 483 observations of deficiencies at its biosimilar insulin aspart manufacturing facility in Malaysia, following an on-site pre-approval inspection conducted by the agency.
However, the Indian firm – which is partnered with Viatris on insulin aspart, with the company having indicated earlier...